A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs APX 3330 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Apexian Pharmaceuticals
  • Most Recent Events

    • 24 Jan 2018 According to an Apexian Pharmaceuticals media release, status changed from not yet recruiting to recruiting.
    • 12 Dec 2017 Status changed from planning to not yet recruiting.
    • 05 Jun 2017 According to an Apexian Pharmaceuticals media release, the company expects to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top